T2 Biosystems Inc. (NASDAQ:TTOO)’s share price dropped 4.6% on Tuesday . The company traded as low as $4.97 and last traded at $5.03, with a volume of 121,766 shares traded. The stock had previously closed at $5.27.

TTOO has been the subject of a number of recent analyst reports. Cantor Fitzgerald reiterated a “buy” rating on shares of T2 Biosystems in a research report on Tuesday, May 3rd. Zacks Investment Research upgraded shares of T2 Biosystems from a “hold” rating to a “buy” rating and set a $8.75 price target for the company in a research report on Tuesday, July 5th. Leerink Swann reiterated a “buy” rating on shares of T2 Biosystems in a research report on Sunday, July 10th. Morgan Stanley reiterated a “hold” rating on shares of T2 Biosystems in a research report on Monday, May 2nd. Finally, BTIG Research lowered shares of T2 Biosystems from a “buy” rating to a “sell” rating and dropped their price target for the stock from $12.00 to $4.00 in a research report on Friday, July 8th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $10.90.

The firm’s market capitalization is $120.93 million. The company’s 50-day moving average is $7.88 and its 200-day moving average is $8.71.

T2 Biosystems (NASDAQ:TTOO) last posted its quarterly earnings results on Monday, May 2nd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by $0.01. The business had revenue of $1.10 million for the quarter. The firm’s revenue was up 485.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.53) earnings per share. Equities research analysts forecast that T2 Biosystems Inc. will post ($2.17) EPS for the current fiscal year.

In other T2 Biosystems news, SVP Rahul Dhanda sold 3,589 shares of the firm’s stock in a transaction that occurred on Thursday, June 30th. The shares were sold at an average price of $8.16, for a total transaction of $29,286.24. Following the completion of the transaction, the senior vice president now directly owns 3,589 shares of the company’s stock, valued at approximately $29,286.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

A hedge fund recently raised its stake in T2 Biosystems stock. Aisling Capital LLC raised its position in T2 Biosystems Inc. (NASDAQ:TTOO) by 12.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,830,992 shares of the company’s stock after buying an additional 307,692 shares during the period. T2 Biosystems accounts for approximately 5.3% of Aisling Capital LLC’s portfolio, making the stock its 6th largest position. Aisling Capital LLC owned approximately 13.89% of T2 Biosystems worth $30,971,000 as of its most recent filing with the SEC.

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.